Epigenetic targets in cancer Kristian Helin

Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Denmark

Professor Kristian Helin is the founding director of the Biotech Research and Innovation Centre (BRIC) at the University of Copenhagen and professor at the Faculty of Health Sciences at the University of Copenhagen. He is also the director of a Centre for Epigenetics and a PI in the Danish Stem Cell Center. Dr. Helin is a co-founder of the biotech company EpiTherapeutics.

Dr Helin obtained his PhD from the University of Copenhagen, and performed post-doctoral work at Harvard Medical School, where he cloned the first member of the E2F transcription factor family. Subsequently, Dr Helin was a group leader at the Danish Cancer Society in Copenhagen and a Division Director at the European Institute of Oncology. Prof. Helin has received numerous awards and is an elected member of EMBO and the Royal Danish Academy of Science and Letters.

The major aim of the research in the Prof. Helin’s group is to elucidate the molecular mechanisms leading to cancer with the aim of identifying novel anti-cancer therapies. In the last 10 years the group has focused on the role of chromatin-associated proteins in stem cells and cancer. This research has led to the identification of novel mechanisms for the control of stem cell self-renewal and differentiation, the identification of novel enzymatic activities regulating histone methylation, and to new insights into how cancer develops.